Cited by 136Monoclonal and Polyclonal Antibodies ResearchSubstance Abuse Treatment and OutcomesImmunotoxicology and immune responses

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Immunotherapy for the treatment of drug abuse

Kosten, Thomas, Owens, S. Michael·2005·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2005.06.009

Open this paper in CoChat — free account

Abstract

Antibody therapy (as either active or passive immunization) is designed primarily to prevent drugs of abuse from entering the central nervous system (CNS). Antidrug antibodies reduce rush, euphoria, and drug distribution to the brain at doses that exceed the apparent binding capacity of the antibody. This is accomplished through a pharmacokinetic antagonism, which reduces the amount of drug in the brain, the rate of clearance across the blood-brain barrier, and the volume of drug distribution. Because the antibodies remain primarily in the circulatory system, they have no apparent central nervous system side effects. Active immunization with drug-protein conjugate vaccines has been tested for cocaine, heroin, methamphetamine, and nicotine in animal, with 1 cocaine and 3 nicotine vaccines in Phase 2 human trials. Passive immunization with high affinity monoclonal antibodies has been tested for cocaine, methamphetamine, nicotine, and phencyclidine (PCP) in preclinical animal models. Antibodies have 2 immediate clinical applications in drug abuse treatment: to treat drug overdose and to reduce relapse to drug use in addicted patients. The specificity of the therapies, the lack of addiction liability, minimal side effects, and long-lasting protection against drug use offer major therapeutic benefit over conventional small molecule agonists and antagonists. Immunotherapies can also be combined with other antiaddiction medications and enhance behavioral therapies. Current immunotherapies already show efficacy, but improved antigen design and antibody engineering promise highly specific and rapidly developed treatments for both existing and future addictions.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2005.06.009

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200
Drug War Heresies
MacCoun, R. J., & Reuter, P. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511754272 · Cited by 677
New generation vaccines
(1992) · International Journal of Biochemistry · doi:10.1016/0020-711x(92)90281-5 · Cited by 673
Clearing the Smoke
Institute of Medicine (2001) · National Academies Press eBooks · doi:10.17226/10029 · Cited by 448
Impact of Highly Active Antiretroviral Treatment on HIV Seroincidence Among Men Who Have Sex With Men: San Francisco
Katz, M. H., Schwarcz, S. K., Kellogg, T. A., Klausner, J. D., Dilley, J., Gibson, S., & McFarland, W. C. (2002) · American Journal of Public Health · doi:10.2105/ajph.92.3.388 · Cited by 385
Clearing the smoke: the science base for tobacco harm reduction—executive summary
Stratton, K., Shetty, P., Wallace, R., & Bondurant, S. (2001) · Tobacco Control · doi:10.1136/tc.10.2.189 · Cited by 313
Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men
Ostrow, D. E., Fox, K., Chmiel, J. S., Silvestre, A. J., Visscher, B. R., Vanable, P. A., Jacobson, L. P., & Strathdee, S. A. (2002) · AIDS · doi:10.1097/00002030-200203290-00013 · Cited by 303
Changes in heroin self-administration by a rhesus monkey after morphine immunisation
Bonese, K., Wainer, B. H., Fitch, F. W., Rothberg, R. M., & Schuster, C. R. (1974) · Nature · doi:10.1038/252708a0 · Cited by 222
Efficacy of a therapeutic cocaine vaccine in rodent models
Fox, B. S., Kantak, K. M., Edwards, M. A., Black, K. M., Bollinger, B. K., Botka, A. J., French, T. L., Thompson, T. L., Schad, V. C., Greenstein, J. L., et al. (1996) · Nature Medicine · doi:10.1038/nm1096-1129 · Cited by 220
Suppression of psychoactive effects of cocaine by active immunization
Carrera, M. R. A., Ashley, J. A., Parsons, L. H., Wirsching, P., Koob, G. F., & Janda, K. D. (1995) · Nature · doi:10.1038/378727a0 · Cited by 220

Show all 63 references

Research works printed but not linked: 2

Lacy, M., & Owens, S. M. (in press). Molecular engineering an anti-PCP chimeric (mouse/human) monoclonal antibody for treatment of human drug abuse. Exp Biol.
Turpen, 1997, Production of recombinant proteins in plants: pharmaceutical applications. The Soc. Exper. Biol., Canterbury, UK, J Exp Bot, 48

Sorted by citations

Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., & Swanson, J. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001507 · Cited by 1,101
Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., Swanson, J. M., & Telang, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1575 · Cited by 605
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 487
New treatments for cocaine dependence: a focused review.
Karila, L., Gorelick, D., Weinstein, A., Noble, F., Benyamina, A., Coscas, S., Blecha, L., Lowenstein, W., Martinot, J., Reynaud, M., et al. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008097 · Cited by 172
The Neurobiology of Addictive Disorders
Ross, S., & Peselow, E. D. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181a9163c · Cited by 136
Cocaine-Specific Antibodies Blunt the Subjective Effects of Smoked Cocaine in Humans
Haney, M., Gunderson, E. W., Jiang, H., Collins, E. D., & Foltin, R. W. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.031 · Cited by 127
A Vaccine Strategy that Induces Protective Immunity against Heroin
Stowe, G. N., Vendruscolo, L. F., Edwards, S., Schlosburg, J. E., Misra, K., Schulteis, G., Mayorov, A. V., Zakhari, J. S., Koob, G. F., & Janda, K. D. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200461m · Cited by 116
Approaches to the development of medications for the treatment of methamphetamine dependence
Vocci, F. J., & Appel, N. M. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01772.x · Cited by 114
Medications for substance use disorders
Douaihy, A. B., Kelly, T. M., & Sullivan, C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.759031 · Cited by 93
Immunopharmacotherapy: Vaccination strategies as a treatment for drug abuse and dependence
Moreno, A. Y., & Janda, K. D. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.01.015 · Cited by 85
Liposomes containing monophosphoryl lipid A: A potent adjuvant system for inducing antibodies to heroin hapten analogs
Matyas, G. R., Mayorov, A. V., Rice, K. C., Jacobson, A. E., Cheng, K., Iyer, M. R., Li, F., Beck, Z., Janda, K. D., & Alving, C. R. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.04.027 · Cited by 81
REVIEW: New developments in the pharmacotherapy of cocaine abuse
Preti, A. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00061.x · Cited by 82
Impact of Distinct Chemical Structures for the Development of a Methamphetamine Vaccine
Moreno, A. Y., Mayorov, A. V., & Janda, K. D. (2011) · Journal of the American Chemical Society · doi:10.1021/ja108807j · Cited by 80
Substance Abuse Vaccines
Orson, F. M., Kinsey, B. M., Singh, R. A. K., Wu, Y., Gardner, T., & Kosten, T. R. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1441.027 · Cited by 79
Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse
Peterson, E. C., Gunnell, M. G., Che, Y., Goforth, R. L., Carroll, F. I., Henry, R. L., Liu, H., & Owens, S. M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.117150 · Cited by 67
Mechanistic insights into nicotine withdrawal
Paolini, M., & De Biasi, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.075 · Cited by 66
A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats
Li, Q., Luo, Y., Sun, C., Xue, Y., Zhu, W., Shi, H., Zhai, H., Shi, J., & Lü, L. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07502.x · Cited by 64
Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines
Duryee, M. J., Bevins, R. A., Reichel, C. M., Murray, J. E., Dong, Y., Thiele, G. M., & Sanderson, S. D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.105 · Cited by 64
A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse
Sulima, A., Jalah, R., Antoline, J. F. G., Torres, O. B., Imler, G. H., Deschamps, J. R., Beck, Z., Alving, C. R., Jacobson, A. E., Rice, K. C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01427 · Cited by 64
Vaccines against stimulants: cocaine and MA
Kosten, T. R., Domingo, C. B., Orson, F. M., & Kinsey, B. M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12115 · Cited by 58
Pharmacotherapy of Addictive Disorders
Ross, S., & Peselow, E. D. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181a91655 · Cited by 57
A Chimeric Human/Murine Anticocaine Monoclonal Antibody Inhibits the Distribution of Cocaine to the Brain in Mice
Norman, A. B., Tabet, M. R., Norman, M. K., Buesing, W. R., Pesce, A. J., & Ball, W. J. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111781 · Cited by 46
AAVrh.10-Mediated Expression of an Anti-Cocaine Antibody Mediates Persistent Passive Immunization That Suppresses Cocaine-Induced Behavior
Rosenberg, J. B., Hicks, M. J., De, B. P., Pagovich, O. E., Frenk, E. Z., Janda, K. D., Wee, S., Koob, G. F., Hackett, N. R., Kaminsky, S. M., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.178 · Cited by 43
Developing a Vaccine Against Multiple Psychoactive Targets: A Case Study of Heroin
Stowe, G. N., Schlosburg, J. E., Vendruscolo, L. F., Edwards, S., Misra, K., Schulteis, G., Zakhari, J. S., Koob, G. F., & Janda, K. D. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711799219316 · Cited by 43
The Effect of a Chimeric Human/Murine Anti-Cocaine Monoclonal Antibody on Cocaine Self-Administration in Rats
Norman, A. B., Norman, M. K., Buesing, W. R., Tabet, M. R., Tsibulsky, V. L., & Ball, W. J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146407 · Cited by 41
Nicotine vaccines to treat tobacco dependence
Goniewicz, M. L., & Delijewski, M. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22060 · Cited by 43
Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction
Owens, S. M., Atchley, W. T., Hambuchen, M. D., Peterson, E. C., & Gentry, W. B. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711799219370 · Cited by 39
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse
Skike, C. E. V., Maggio, S. E., Reynolds, A. R., Casey, E. M., Bardo, M. T., Dwoskin, L. P., Prendergast, M., & Nixon, K. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.004 · Cited by 43
The genetics of nicotine addiction liability: ethical and social policy implications
Hall, W., GARTNER, C. E., & Carter, A. (2008) · Addiction · doi:10.1111/j.1360-0443.2007.02070.x · Cited by 38
A Role for mGluR5 Receptors in Intravenous Methamphetamine Self‐Administration
Osborne, M. P. H., & Olive, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1432.034 · Cited by 37
Role of plant expression systems in antibody production for passive immunization
Virdi, V., & Depicker, A. (2013) · The International Journal of Developmental Biology · doi:10.1387/ijdb.130266ad · Cited by 36
Cocaine Hydrolase Encoded in Viral Vector Blocks the Reinstatement of Cocaine Seeking in Rats for 6 Months
Anker, J. J., Brimijoin, S., Gao, Y., Geng, L., Zlebnik, N. E., Parks, R. J., & Carroll, M. E. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.014 · Cited by 35
A Recombinant Humanized Anti-Cocaine Monoclonal Antibody Inhibits the Distribution of Cocaine to the Brain in Rats
Norman, A. B., Gooden, F., Tabet, M. R., & Ball, W. J. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057034 · Cited by 33
Combined Cocaine Hydrolase Gene Transfer and Anti-Cocaine Vaccine Synergistically Block Cocaine-Induced Locomotion
Carroll, M. E., Zlebnik, N. E., Anker, J. J., Kosten, T. R., Orson, F. M., Shen, X., Kinsey, B. M., Parks, R. J., Gao, Y., & Brimijoin, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043536 · Cited by 32
The Dopamine Uptake Inhibitor 3α-[bis(4′-fluorophenyl)metoxy]-tropane Reduces Cocaine-Induced Early-Gene Expression, Locomotor Activity, and Conditioned Reward
Velázquez-Sánchez, C., Ferragud, A., Hernández‐Rabaza, V., Nácher, A., Merino, V., Cardá, M., Murga, J., & Canales, J. J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.78 · Cited by 32
A Conjugate Vaccine Attenuates Morphine- and Heroin-Induced Behavior in Rats
Li, Q., Sun, C., Luo, Y.-X., Xue, Y.-X., Meng, S., Xu, L., Chen, N., Deng, J.-H., Zhai, H., Kosten, T. R., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu093 · Cited by 32
The concept of pharmacologic cocaine interception as a treatment for drug abuse
Gao, Y., Orson, F. M., Kinsey, B. M., Kosten, T., & Brimijoin, S. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.02.036 · Cited by 31
Decreased reinforcing effects of cocaine following two weeks of continuous d-amphetamine treatment in rats
Chiodo, K. A., & Roberts, D. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1622-4 · Cited by 34
Is immunotherapy an opportunity for effective treatment of drug addiction?
Zalewska-Kaszubska, J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.079 · Cited by 31
Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection
Hendrickson, H. P., Laurenzana, E. M., & Owens, S. M. (2006) · The AAPS Journal · doi:10.1208/aapsj080480 · Cited by 31
Immunotherapy for Drug Abuse
Shen, X. Y., & Kosten, T. R. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711799219352 · Cited by 30
Promising Medications for Cocaine Dependence Treatment
Somaini, L., Donnini, C., Raggi, M. A., Amore, M., Ciccocioppo, R., Saracino, M. A., Kallupi, M., Malagoli, M., Gerra, M. L., & Gerra, G. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488911795933893 · Cited by 29
Differential Effects of Passive Immunization with Nicotine-Specific Antibodies on the Acute and Chronic Distribution of Nicotine to Brain in Rats
Pentel, P. R., Dufek, M. B., Roiko, S. A., LeSage, M. G., & Keyler, D. E. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097873 · Cited by 29
Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats
Laurenzana, E. M., Hendrickson, H. P., Carpenter, D. O., Peterson, E. C., Gentry, W. B., West, M. R., Che, Y., Carroll, F. I., & Owens, S. M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.072 · Cited by 28
A Monoclonal Antibody Specific for 6-Monoacetylmorphine Reduces Acute Heroin Effects in Mice
Bogen, I. L., Boix, F., Nerem, E., Mørland, J. G., & Andersen, J. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212035 · Cited by 27
Lasting Reduction of Cocaine Action in Neostriatum— A Hydrolase Gene Therapy Approach
Gao, Y., & Brimijoin, S. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152231 · Cited by 26
Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse—Methamphetamine and 3,4‐methylenedioxymethamphetamine
Celikel, R., Peterson, E. C., Owens, S. M., & Varughese, K. I. (2009) · Protein Science · doi:10.1002/pro.244 · Cited by 23
Vaccine development against methamphetamine drug addiction
Hossain, M. K., Hassanzadeganroudsari, M., Nurgali, K., & Apostolopoulos, V. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1857738 · Cited by 23
Immune to addiction: the ethical dimensions of vaccines against substance abuse
Young, M. J., Sisti, D. A., Rimon-Greenspan, H., Schwartz, J. L., & Caplan, A. L. (2012) · Nature Immunology · doi:10.1038/ni.2321 · Cited by 21
Suppression of Nicotine-Induced Pathophysiology by an Adenovirus Hexon-Based Antinicotine Vaccine
Rosenberg, J. B., De, B. P., Hicks, M. J., Janda, K. D., Kaminsky, S. M., Worgall, S., & Crystal, R. G. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.245 · Cited by 21
Pharmacological Effects of a Monoclonal Antibody against 6-Monoacetylmorphine upon Heroin-Induced Locomotor Activity and Pharmacokinetics in Mice
Kvello, A. M. S., Andersen, J. M., Øiestad, E. L., Mørland, J. G., & Bogen, I. L. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233510 · Cited by 19
Vaccines to combat smoking
Bevins, R. A., Wilkinson, J. L., & Sanderson, S. D. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.379 · Cited by 18
Immune to addiction: how immunotherapies can be used to combat methamphetamine addiction
Hossain, M. K., Hassanzadeganroudsari, M., Kypreos, E., Feehan, J., & Apostolopoulos, V. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1927725 · Cited by 17
Designing Immunotherapies to Thwart Drug Abuse
Peterson, E. C., & Owens, S. M. (2009) · Molecular Interventions · doi:10.1124/mi.9.3.5 · Cited by 16
Immunopharmacotherapeutic advancements in addressing methamphetamine abuse
Lee, J. C., & Janda, K. D. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00165a · Cited by 16
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
Han, R., Wang, Y., & Lu, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010059 · Cited by 18
A Vaccine against Benzimidazole-Derived New Psychoactive Substances That Are More Potent Than Fentanyl
Lee, J. C., Park, H., Eubanks, L. M., Ellis, B. A., Zhou, B., & Janda, K. D. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01967 · Cited by 15
Domain unfolding of monoclonal antibody fragments revealed by non-reducing SDS-PAGE
Kirley, T. L., Greis, K. D., & Norman, A. B. (2018) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2018.10.004 · Cited by 15
Positional linker effects in haptens for cocaine immunopharmacotherapy
Ino, A., Dickerson, T. J., & Janda, K. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.032 · Cited by 14
Interception of Cocaine by Enzyme or Antibody Delivered with Viral Gene Transfer: A Novel Strategy for Preventing Relapse in Recovering Drug Users
Brimijoin, S. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711799219398 · Cited by 13
Predicting the Clinical Efficacy and Potential Adverse Effects of a Humanized Anticocaine Monoclonal Antibody
Norman, A. B., & Ball, W. J. (2012) · Immunotherapy · doi:10.2217/imt.12.19 · Cited by 13
A naturalistic longitudinal analysis of post‐detoxification outcomes in opioid‐dependent patients
Ivers, J., Zgaga, L., Sweeney, B., Keenan, E., Darker, C. D., Smyth, B. P., & Barry, J. M. (2017) · Drug and Alcohol Review · doi:10.1111/dar.12597 · Cited by 13
Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody
Lacy, H. M., Gunnell, M. G., Laurenzana, E. M., & Owens, S. M. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.09.020 · Cited by 12
Antibody-catalyzed anaerobic destruction of methamphetamine
Xu, Y. Y., Hixon, M. S., Yamamoto, N., McAllister, L. A., Wentworth, A. D., Wentworth, P., & Janda, K. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611094104 · Cited by 12
Treatment of methamphetamine abuse: An antibody-based immunotherapy approach
Chen, Y., Wu, K., Tsai, H.-M., & Chen, C. (2013) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2013.09.040 · Cited by 12
Identification of Treatment Targets in a Genetic Mouse Model of Voluntary Methamphetamine Drinking
Phillips, T. J., Mootz, J. R. K., & Reed, C. L. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.001 · Cited by 12
A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys
Galbo, L. K., Marecki, C., Kim, C. M., Hiranita, T., Taylor, J. R., Maguire, D. R., Hicks, D. M., Gebo, A., Khaimraj, A., Baehr, C., et al. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06751-9 · Cited by 10
Cross-Reactivity of Selected Benzofurans with Commercial Amphetamine and Ecstasy Immunoassays in Urine
Gomila, I., Moranta, C., Quesada, L., Pastor, Y., Dastis-Arias, M., Torrents, A., Elorza, M. Á., Busardò, F. P., & Martín, B. B. (2017) · Bioanalysis · doi:10.4155/bio-2017-0191 · Cited by 10
Development of an Effective Monoclonal Antibody against Heroin and Its Metabolites Reveals Therapies Have Mistargeted 6-Monoacetylmorphine and Morphine over Heroin
Lee, J. C., Eubanks, L. M., Zhou, B., & Janda, K. D. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00977 · Cited by 10
Enhancing Protective Antibodies against Opioids through Antigen Display on Virus-like Particles
Shafieichaharberoud, F., Lang, S., Whalen, C., Quiles, C. R., Purcell, L., Talbot, C., Wang, P., Norton, E. B., Mazei‐Robison, M. S., Sulima, A., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00415 · Cited by 10
Structural analysis of free and liganded forms of the Fab fragment of a high-affinity anti-cocaine antibody, h2E2
Tan, K., Zhou, M., Ahrendt, A. J., Duke, N. E. C., Tabaja, N., Ball, W. J., Kirley, T. L., Norman, A. B., Joachimiak, A., Schiffer, M., et al. (2019) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x19013608 · Cited by 10
Recombinant Adeno-Associated Virus-Mediated Expression of Methamphetamine Antibody Attenuates Methamphetamine-Induced Hyperactivity in Mice
Chen, Y., Wu, K., Wu, K.-L., Wu, K.-L., Tsai, H.-M., Chen, M.-L., Chen, Y.-W., Hsieh, W., Lin, C.-M., & Wang, Y. (2017) · Scientific Reports · doi:10.1038/srep46301 · Cited by 10
Ethical implications of research on craving
Carter, A., & Hall, W. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.07.002 · Cited by 9
Customizing Monoclonal Antibodies for the Treatment of Methamphetamine Abuse
Peterson, E. C., Gentry, W. B., & Owens, S. M. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00003-2 · Cited by 9
Ethical Implications in Vaccine Pharmacotherapy for Treatment and Prevention of Drug of Abuse Dependence
Carfora, A., Cassandro, P., Feola, A., Sala, F., Petrella, R., & Borriello, R. (2018) · Journal of Bioethical Inquiry · doi:10.1007/s11673-017-9834-5 · Cited by 9
A Recombinant Humanized Anticocaine Monoclonal Antibody Alters the Urinary Clearance of Cocaine and Its Metabolites in Rats
Marckel, J. A., Wetzel, H. N., Amlal, S., Amlal, H., & Norman, A. B. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083857 · Cited by 8
Vaccination against smoking: an annotated agenda for debate. A review of scientific journals, 2001–13
Wolters, A., de Wert, G. M. W. R., van Schayck, O. C. P., & Horstman, K. (2014) · Addiction · doi:10.1111/add.12572 · Cited by 7
Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats
Hubbard, J. J., Laurenzana, E. M., Williams, D. K., Gentry, W. B., & Owens, S. M. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.09.016 · Cited by 7
Development of fentanyl-specific monoclonal antibody (mAb) to antagonize the pharmacological effects of fentanyl
Chen, X.-Y., Wang, L., Ma, X., Yang, F., Wang, X., Xu, P., Xu, L., & Di, B. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116918 · Cited by 8
Structural Characterization of a Therapeutic Anti-Methamphetamine Antibody Fragment: Oligomerization and Binding of Active Metabolites
Peterson, E. C., Celikel, R., Gokulan, K., & Varughese, K. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082690 · Cited by 7
Electrophoretic Profile of Serum Proteins in Opium and Heroin Dependents
Divsalar, K., Meymandi, M. S., Saravani, R., Zarandi, M. M., & Shaikh-al-eslami, A. (2008) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802406686 · Cited by 7
Prevention of Drug-Induced Memory Impairment by Immunopharmacotherapy
Treweek, J. B., Sun, C., Mayorov, A. V., Qi, L., Levy, C. L., Roberts, A. J., Dickerson, T. J., & Janda, K. D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800506v · Cited by 7
A mathematical model of a recombinant humanized anti-cocaine monoclonal antibody's effects on cocaine pharmacokinetics in mice
Wetzel, H. N., Zhang, T., & Norman, A. B. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.07.006 · Cited by 7
Current status of vaccines in psychiatry—A narrative review
Kuppili, P. P., Manohar, H., & Menon, V. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.02.004 · Cited by 7
Pills for speedballing or cocaine dependence.
Johnson, B. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68749-7 · Cited by 7
A humanized anti‐cocaine mAb antagonizes the cardiovascular effects of cocaine in rats
Koch, S. E., Marckel, J. A., Rubinstein, J., & Norman, A. B. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1045 · Cited by 6
Vaccines in the Treatment of Substance Abuse
Shorter, D. I., & Kosten, T. R. (2011) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.9.1.foc25 · Cited by 6
Development of effective therapeutics for polysubstance use disorders
Lee, J. C., & Janda, K. D. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102105 · Cited by 6
Drogenmissbrauch und -abhängigkeit
Küfner, H., Metzner, C., & Bühringer, G. (2006) · Springer eBooks · doi:10.1007/978-3-540-28511-3_33 · Cited by 5
Biopharmaceuticals against substance use disorders – Present and future
Vavilis, T., Stamoula, Ε., Sachinidis, A., Lamprinou, M., Dardalas, I., & Papazisis, G. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175587 · Cited by 6
Modulation of Attentional Bias to Drug and Affective Cues by Therapeutic and Neuropsychological Factors in Patients With Opioid Use Disorder on Methadone Maintenance Therapy
Li, W., Huang, J., Zhang, N., Weidacker, K., Li, J., Voon, V., Wang, C., & Zhang, C. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780208 · Cited by 4
A methamphetamine vaccine using short monoamine and diamine peptide linkers and poly-mannose
Hossain, M. K., Davidson, M., Feehan, J., Matsoukas, J., Nurgali, K., & Apostolopoulos, V. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117930 · Cited by 4
Emerging Neurobiological Treatments of Addiction
Carter, A., Capps, B., & Hall, W. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-385973-0.00005-3 · Cited by 4
Drogenmissbrauch und -abhängigkeit
Küfner, H., & Metzner, C. (2011) · Springer-Lehrbuch · doi:10.1007/978-3-642-13018-2_34 · Cited by 4
The Ethical Use of Psychosocially Assisted Pharmacological Treatments for Opioid Dependence
Carter, A., & Hall, W. (2007) · Cited by 4
Antibody immunotherapies for personalized opioid addiction treatment
Rosenn, E. H., Korlansky, M., Benyaminpour, S., Munarova, V., Fox, E., Shah, D., Durham, A., Less, N., & Pasinetti, G. M. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103522 · Cited by 3
Cloning and Characterization of a Hybridoma Secreting a 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-Specific Monoclonal Antibody and Recombinant F(ab)
Wanczyk, H., Barker, T. T., Rood, D., Zapata, D., Howell, A. R., Richardson, S. K., Zinckgraf, J. W., Marusov, G., Lynes, M. A., & Silbart, L. K. (2013) · Toxins · doi:10.3390/toxins5030568 · Cited by 3
Design of cocaethylene and cocaine conjugates to produce highly selective polyclonal antibodies.
Gadjou, C., Danger, Y., Sandouk, P., Scherrmann, J., Blanchard, D., Folléa, G., & Galons, H. (2006) · Europe PMC (PubMed Central) · Cited by 3
Vaccines for Treating Cocaine Use Disorders
Domingo, C. B., Shorter, D. I., & Kosten, T. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-23150-1_3 · Cited by 3
Medications for Substance Use Disorders
Daley, D. C., & Douaihy, A. B. (2019) · Oxford University Press eBooks · doi:10.1093/med-psych/9780190926717.003.0006 · Cited by 3

Authors: Kosten, T., & Owens, S. M.
Affiliations: Yale University (US)
University of Arkansas for Medical Sciences (US)
Corresponding author: Kosten, Thomas
ORCID: Kosten, Thomas
Owens, S. Michael
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2005-10
Volume: 108
Issue: 1
Pages: 76-85
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2005.06.009
OpenAlex: W2089434413
Cited by: 135
References: 63
Citations by year: 2025: 4 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 4 · 2017: 6 · 2016: 3 · 2015: 5 · 2014: 10 · 2013: 8 · 2012: 6
FWCI: 1.51
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Drug Abuse (K05DA000454, U19DA010946, P50DA012762, P50DA018197, R01DA015477, R01DA011560, R01DA007610, P01DA014361)
NIH Clinical Center
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords: antibody therapy, addiction treatment, active immunization, passive immunization, monoclonal antibodies, cocaine, heroin, methamphetamine, nicotine, phencyclidine, blood-brain barrier, drug overdose treatment, relapse prevention, addiction liability, antibody engineering, antigen design
MeSH terms: Animals, Antibodies, Monoclonal, Humans, Immunotherapy, Vaccines, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunotherapy for the treatment of drug abuse

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks